These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

49 related articles for article (PubMed ID: 6482811)

  • 1. Phenylbutazone off benefits list.
    Smith GL
    Med J Aust; 1984 Oct; 141(8):551-2. PubMed ID: 6482811
    [No Abstract]   [Full Text] [Related]  

  • 2. Phenylbutazone off benefits list.
    Auerbach E
    Med J Aust; 1984 Aug; 141(4):261-2. PubMed ID: 6332972
    [No Abstract]   [Full Text] [Related]  

  • 3. Phenylbutazone.
    Mansfield P
    Med J Aust; 1985 Sep; 143(5):219-20. PubMed ID: 4033497
    [No Abstract]   [Full Text] [Related]  

  • 4. Phenylbutazone, oxyphenbutazone labeling revised.
    FDA Drug Bull; 1984 Dec; 14(3):23-4. PubMed ID: 6526172
    [No Abstract]   [Full Text] [Related]  

  • 5. [New CsL3 drugs and their control testing--oscillopolarographic study of ketophenyl-butazone].
    Faith L; Citovická N
    Cesk Farm; 1968 Nov; 17(9):409-15. PubMed ID: 5719814
    [No Abstract]   [Full Text] [Related]  

  • 6. Pharmaceutical benefits: deletion of "priscol", "ronicol" and "dibenyline".
    Bryson AM
    Med J Aust; 1971 Feb; 1(7):406-7. PubMed ID: 5553152
    [No Abstract]   [Full Text] [Related]  

  • 7. Phenylbutazone.
    Smith GL
    Med J Aust; 1980 Jan; 1(2):82. PubMed ID: 7360097
    [No Abstract]   [Full Text] [Related]  

  • 8. Off-label pharmaceutical use: balancing information, risks, and benefits.
    Kozma CM
    Manag Care Interface; 2004 Jan; 17(1):29-30. PubMed ID: 15035597
    [No Abstract]   [Full Text] [Related]  

  • 9. Health insurance oversight issue brief: mandated benefits: off-label drug coverage requirements: year end report--2004.
    Plaza CI
    Issue Brief Health Policy Track Serv; 2004 Dec; ():1-9. PubMed ID: 15726733
    [No Abstract]   [Full Text] [Related]  

  • 10. Finance issue brief: mandated benefits: off-label drug coverage requirements: year end report-2003.
    Plaza CI
    Issue Brief Health Policy Track Serv; 2003 Dec; ():1-9. PubMed ID: 14870745
    [No Abstract]   [Full Text] [Related]  

  • 11. Pharmaceuticals, finance issue brief: mandated benefits: off-label drug coverage.
    Plaza CI
    Issue Brief Health Policy Track Serv; 2000 Jun; ():1-5. PubMed ID: 11073410
    [No Abstract]   [Full Text] [Related]  

  • 12. Satisfaction with pharmacotherapy for approved and off-label indications--a Delphi study.
    Kos M; Wertheimer AI; Mrhar A
    Ann Pharmacother; 2005 Apr; 39(4):649-54. PubMed ID: 15755789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AVMA/Practice Group perspectives: use of drug labels in the prescription of antimicrobial therapy. Representing the American Association of Equine Practitioners (AAEP).
    White NA
    J Am Vet Med Assoc; 1995 Oct; 207(7):884-5; discussion 890-4. PubMed ID: 7559014
    [No Abstract]   [Full Text] [Related]  

  • 14. Compounded medicines and 'off label' prescribing - a case for more guidance.
    Fois RA; Mewes BT; McLachlan AJ; Ramzan I
    Aust Fam Physician; 2009; 38(1-2):16-20. PubMed ID: 19283230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interaction of phenylbutazone and tolbutamide in man.
    Szita M; Gachályi B; Tornyossy M; Káldor A
    Int J Clin Pharmacol Ther Toxicol; 1980 Sep; 18(9):378-80. PubMed ID: 7450929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Off label drug use in adult patients treated by anticancer chemotherapy].
    Levêque D; Michallat AC; Schaller C; Ranc M
    Bull Cancer; 2005 May; 92(5):498-500. PubMed ID: 15932813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug interaction between chlorpropamide and non-steroidal anti-inflammatory drugs, ibuprofen and phenylbutazone.
    Shah SJ; Bhandarkar SD; Satoskar RS
    Int J Clin Pharmacol Ther Toxicol; 1984 Sep; 22(9):470-2. PubMed ID: 6500764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Misuse of veterinary phenylbutazone.
    Carpenter SL; McDonnell WM
    Arch Intern Med; 1995 Jun; 155(11):1229-31. PubMed ID: 7763130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Sweet's syndrome and phenylbutazone-induced sialadenitis].
    Levang J; Muller P; Girardin P; Humbert P
    Ann Dermatol Venereol; 2008 Apr; 135(4):291-4. PubMed ID: 18420076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Phenylbutazone-induced sialadenitis fever simulating angioedema].
    Viseux V; Béguin L; Poulain JF; Sarraj A; Mayeux I; Carmi E; Lafon B; Lok C
    Ann Dermatol Venereol; 2002 Jan; 129(1 Pt 1):59-62. PubMed ID: 11937933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.